Evidence map›Paper›PMID 31671767›Full record

ArticleMolecules (Basel, Switzerland)2019

Anti-Cancer and Ototoxicity Characteristics of the Curcuminoids, CLEFMA and EF24, in Combination with Cisplatin.

Jerry D Monroe, Denis Hodzic, Matthew H Millay, Blaine G Patty, Michael E Smith

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jerry D MonroeDepartment of Biology, Western Kentucky University, 1906 College Heights Boulevard, #11080, Bowling Green, KY 42101-1080, USA. jerry.monroe@wku.edu.
Denis HodzicDepartment of Biology, Western Kentucky University, 1906 College Heights Boulevard, #11080, Bowling Green, KY 42101-1080, USA. denis.hodzic021@topper.wku.edu.
Matthew H MillayDepartment of Biology, Western Kentucky University, 1906 College Heights Boulevard, #11080, Bowling Green, KY 42101-1080, USA. matthew.millay602@topper.wku.edu.
Blaine G PattyDepartment of Biology, Western Kentucky University, 1906 College Heights Boulevard, #11080, Bowling Green, KY 42101-1080, USA. blaine.patty739@topper.wku.edu.
Michael E SmithDepartment of Biology, Western Kentucky University, 1906 College Heights Boulevard, #11080, Bowling Green, KY 42101-1080, USA. michael.smith1@wku.edu.ORCID 0000-0002-2174-9825
Western Kentucky University · US

Funding

Finding novel platinum(II) complex anti-cancer drugs with reduced ototoxicityR15CA188890 · NCI · WESTERN KENTUCKY UNIVERSITY · PI SMITH, MICHAEL E, WILLIAMS, KEVIN M · 2015 to 2015
$414k
NCI NIH HHS T1 R15 CA188890-01A1NIH HHS 2 P20 GM103436-14NIH HHS 8 P20GM103436-12
6 · The paper itself

Abstract

In this study, we investigated whether the curcuminoids, CLEFMA and EF24, improved cisplatin efficacy and reduced cisplatin ototoxicity. We used the lung cancer cell line, A549, to determine the effects of the curcuminoids and cisplatin on cell viability and several apoptotic signaling mechanisms. Cellular viability was measured using the MTT assay. A scratch assay was used to measure cell migration and fluorescent spectrophotometry to measure reactive oxygen species (ROS) production. Western blots and luminescence assays were used to measure the expression and activity of apoptosis-inducing factor (AIF), caspases-3/7, -8, -9, and -12, c-Jun N-terminal kinases (JNK), mitogen-activated protein kinase (MAPK), and proto-oncogene tyrosine-protein kinase (Src). A zebrafish model was used to evaluate auditory effects. Cisplatin, the curcuminoids, and their combinations had similar effects on cell viability (IC

Indexed as

A549 CellsAnimalsAntineoplastic AgentsBenzylidene CompoundsCaspasesCell DeathCisplatinDiarylheptanoidsEvoked Potentials, AuditoryHumansInhibitory Concentration 50OtotoxicityPiperidonesProto-Oncogene MasZebrafish3,5-bis(2-fluorobenzylidene)piperidin-4-one4-(3,5-bis(2-chlorobenzylidene)-4-oxopiperidine-1-yl)-4-oxo-2-butenoic acidAntineoplastic AgentsBenzylidene CompoundsCaspasesCisplatinDiarylheptanoidsMAS1 protein, humanPiperidonesProto-Oncogene Masapoptosisauditory evoked potentialcancercell migrationcisplatincurcuminoidreactive oxygen specieszebrafish

Identifiers

PMID31671767
PMCPMC6864451
OpenAlexW2982406886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.